Chemoprevention of Oral Premalignant Lesions

• Status: Completed
• Trial end date: 2004-04-01
• Target enrollment: 0
• Participant gender: All

Summary

Reduction in size and number of oral premalignant lesions

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Celecoxib

Criteria

Inclusion Criteria:

• 8mm oral premalignant lesion that has not been biopsied in the past 6 months

Exclusion Criteria:

• Taking >100mg daily dose of NSAIDS (Non-steroidal anti-inflammatory drugs)